Patents Assigned to Pacific Northwest Biotechnology Inc.
  • AT4 receptor ligands as angiogenic, anti-angiogenic, and anti-tumor agents
    Patent number: 7118747
    Abstract: AT4 receptor agonists are potent activators of angiogenesis and can be used to treat diseases that are characterized by vascular insufficiency. AT4 receptor antagonists, which are potent inhibitors of angiogenesis, and can be used as anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerotic plaque formation, and any disease process that is characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: October 10, 2006
    Assignees: Pacific Northwest Biotechnology Inc., Washington State University Research Foundation
    Inventors: Joseph W Harding, John W Wright
  • AT4 receptor ligands as angiogenic, anti-angiogenic, and anti-tumor agents
    Publication number: 20060128630
    Abstract: AT4 receptor agonists are potent activators of angiogenesis and can be used to treat diseases that are characterized by vascular insufficiency. AT4 receptor antagonists, which are potent inhibitors of angiogenesis, and can be used as anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerotic plaque formation, and any disease process that is characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells.
    Type: Application
    Filed: November 16, 2005
    Publication date: June 15, 2006
    Applicants: Pacific Northwest Biotechnology Inc., Washington State University Research Foundation
    Inventors: Joseph Harding, John Wright
  • AT4 RECEPTOR LIGANDS AS ANGIOGENIC, ANTI-ANGIOGENIC, AND ANTI-TUMOR AGENTS
    Publication number: 20050222044
    Abstract: AT4 receptor agonists are potent activators of angiogenesis and can be used to treat diseases that are characterized by vascular insufficiency. AT4 receptor antagonists, which are potent inhibitors of angiogenesis, and can be used as anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerotic plaque formation, and any disease process that is characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells.
    Type: Application
    Filed: September 30, 2003
    Publication date: October 6, 2005
    Applicant: Pacific Northwest Biotechnology, Inc.
    Inventors: Joseph Harding, John Wright